Recital 105, Decision_act (EU) 2018/9019

In forcesince 29 Oct 2018

The Notifying Party argues that no competition concerns arise as a result of the

Transaction, and in particular that there is no prospect of customer foreclosure, or input foreclosure, for a number of reasons. First, Mars' shares upstream and AniCura's shares downstream are not significant. Although Mars' shares may be above [30-40]% in a number of markets, significant competitors exist and continue to exert competitive pressure. Similarly, AniCura's shares in veterinary services are limited, representing less than [10-20]% of practices, less than [20- 30]% of veterinary service revenues and less than [10-20]% of veterinarians at national level.